In brief: Chemeq, Acuron, Compumedics, Synchrotron

By Staff Writers
Tuesday, 19 July, 2005

Chemeq (ASX:CMQ) is in a trading halt in the lead-up to an announcement concerning the underwriting of AUD$20 million convertible bonds to Mizuho International, Stark Trading and Shephard Investments International, to which it committed itself in April.

Acuron's (ASX:AVP) wholly owned subsidiary Protex Healthcare (UK) will bring its sales and marketing activities in house by appointing medical and wound care sales representatives over the next few months. Meanwhile, Acuron appointed Fiona Taylor as company secretary, replacing Stephen Belben who will remain as finance director.

Compumedics (ASX:CMP) has reinforced its commitment to Asian sales growth with the appointment of Tim Gresham as Business Director, Asia and South American and Ben So as Senior Business Manager Asia.

The Australian Synchrotron and China's Beijing Synchrotron Radiation Facility have signed a collaboration partnership agreement allowing scientists to move freely between the two facilities. The Beijing Synchrotron Radiation Facility is part of the Institute of High Energy Physics within the Chinese Academy of Science.

Related News

The University of Sydney formalises cervical cancer elimination partnership

The success of a cervical cancer elimination program has led to the signing of a memorandum of...

Noxopharm says paper reveals science behind its immune system platform

Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...

Neurosensing/neurostimulation implants session to be held on Monday

On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd